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risk. Automated edit checks of primary data endpoints should be programmed into 
the EDC system prompting data abstractors to revise erroneous data and/or confirm 
data outside of expected ranges at entry. To confirm abstracted data reflect source 
documents (patient medical charts), a second abstractor at the site can re-abstract 
pre-defined critical study variables from patient medical charts for cross-referencing 
for data discrepancies. Site training must be effective to ensure compliance with 
chart abstraction and data quality requirements. ConClusions: Given the fre-
quent incomplete or poor quality medical chart information and the potential for 
human error in data abstraction and entry processes, data quality control methods 
are paramount. Approaches to protocol, CRF and study training materials design 
can positively impact data quality.
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objeCtives: Health technology assessment typically involves consideration of mul-
tiple conflicting criteria. Therefore, trade-offs are required between different objec-
tives such as maximizing health, restricting budget impact, increasing health equity 
and maximizing safety. Methods such as multiple decision criteria analysis (MCDA) 
are therefore increasingly being used to reflect such trade-offs in a transparent 
and consistent manner. Although MCDA can be combined with cost-effectiveness 
analysis it may, however, invalidate results from Value of Information (VOI) analysis 
when it also includes other health-related or cost-related objectives. Methods: In 
two case studies we first applied VOI methods directly and only to cost-effectiveness 
estimates, and then also applied these methods separately to all relevant deci-
sion criteria. In a simulation study on two drugs we calculated the expected value 
of perfect information (EVPI) with drug selection concerning a trade-off between 
cost-effectiveness and drug safety. In a clinical study on the primary prevention of 
cardiovascular disease using improved versus standard risk prediction we calculated 
the EVPI with selection of the best risk prediction strategy concerning a trade-off 
between cost-effectiveness and budget impact. Results: In our simulation study 
we found EVPI estimates per patient based only on cost-effectiveness were up to 
€ -586 lower and € +459 higher compared to EVPI estimates also acknowledging 
the safety criterion, depending on its weight. In our clinical study, the EVPI esti-
mates based only on cost-effectiveness were consistently lower, up to € -540 per 
patient, compared to EVPI estimates also acknowledging the budget impact cri-
terion. ConClusions: When decisions are based not only on cost-effectiveness 
but on other criteria as well, some of which also relate to costs or health effects, 
standard VOI estimates are no longer valid. However, separate application of VOI 
methods to each of the relevant decision criteria is straightforward and can facilitate 
transparent research prioritization in a complex MCDA context.
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The benefits and value of new cancer treatments often focus on the overall survival 
(OS) gains that patients may derive. Trials are typically not long enough to allow 
detailed understanding of OS, and potential benefits must be inferred from benefits 
on progression-free-survival (PFS). This raises questions such as whether early or later 
progression impacts survival, whether the increase in mortality following progression 
is sustained or gradually diffused, and whether a benefit observed on PFS implies a 
benefit in OS. Answering these questions requires an analytical framework in which 
progression and survival can be analyzed together and parameterized to address key 
questions. We propose a statistical modeling framework based on Cox regression and 
time-dependent predictors and effects. A simple formulation of this model would 
include a time-dependent indicator for progression, whose coefficient would meas-
ure the increase in risk of death following the event. This is very limiting, however; 
it assumes that the timing of progression does not matter and that the increase in 
risk of death is sustained indefinitely. A more flexible formulation can be built using 
two descriptors of event: the timing of progression (TP) and time since progression 
(TSP). These can be continuous measures or categorized (e.g., early vs. late TP), as 
appropriate. The coefficient for TP reveals whether later progression is associated 
with higher/lower subsequent mortality, while the coefficient of TSP reflects whether 
and for how long the increase/decrease in mortality is sustained and whether it ever 
returns to the level of patients who had not progressed. The impact of treatment can 
be captured on each of these parameters separately. The proposed framework will 
be illustrated with an example, and extension of the approach to other applications 
(e.g., measuring the impact of a stroke on survival) will be discussed.
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Despite the availability of a large body of research evidence on patient preferences 
for health outcomes and/or health care services, its use in health care policy deci-
sions is limited. This contrasts with the current increasing attention for patient-cen-
the use of e-health interventions.*Both B. F. M. Wijnen and L. A. M. Leenen con-
tributed equally to this work.
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objeCtives: In the absence of secondary sources of health care data, chart review 
studies can result in patient level data repositories including patient characteris-
tics, care patterns, treatment effectiveness and clinical and safety outcomes. Data 
can be used to populate economic evaluations, and value dossiers, and inform 
drug safety assessments. For successful implementation, however, knowledge of 
country-specific ethics and regulatory approval processes is paramount. Methods: 
Operational, ethics and regulatory issues and considerations as well as strategies for 
study success have been summarized in the context of eleven recent multi-national 
chart review case studies. Results: Two of 11 studies also collected data prospec-
tively; two studies were categorized as post authorization safety studies and three 
studies were conducted in peri-approval compassionate use program populations. 
The majority of studies (9) were oncology focused, with two studies focused on 
infectious diseases and opioid-induced constipation. Sample sizes varied from 20 
to 500 patients, the number of countries from 1 to 8, and the number of sites from 4 
to 61. All studies included at least one European country. Across studies, key opera-
tional considerations that impacted the ethical/regulatory approval process were 
ambiguous/amorphous multinational regulatory requirements/guidelines; com-
mercial availability or non-availability of the sponsor product at the time of chart 
abstraction; data collection method(s) (i.e., retrospective vs. hybrid chart review plus 
prospective data collection); country variation in informed consent requirements 
and definitions of personal data; and multinational contractual requirements with 
the participating sites. ConClusions: International chart review studies are an 
effective methodology to resolve data gaps not solved by existing secondary health 
care data sources resulting in tailored, patient-level datasets. Current knowledge of 
the highly variable and evolving global regulatory requirements, as well as the devel-
opment of a risk management plan informed by methodological and operational 
lessons learned at study-outset will facilitate risk mitigation and allow researchers 
to overcome key challenges.
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objeCtives: In addition to study outcome concerns arising from patients lost to 
follow-up (LFU) in pharmacoepidemiology and pharmacovigilance studies, the 
financial impact of LFU can be significant. Our objectives were to estimate cost 
per patient in Non-interventional studies, to identify variables that may affect this 
patient cost, to estimate cost of patient lost to follow-up (LFU), and financial benefits 
that can be expected from LFU minimization through Direct to Patient Contact ser-
vice (DPC). Methods: Analysis of 2013 proposals and budgets submitted to study 
sponsors. Selection criteria: non interventional, prospective, longitudinal patient fol-
low-up, full CRO services. Analysis were performed according to patient sample size, 
study duration, disease category, and different hypothesis for LFU rates. Results: 
1) 20 studies (Domestic, Regional or Global) met all inclusion criteria; 2) Annual 
cost per patient -ranging from € 1,068 to € 4,370- decreases as the study duration 
increases (set-up cost is more diluted in the patient annual cost). But the longer the 
study is the more expensive the overall cost per patient; 3) Mean annual patient cost 
significantly differs according to rarity of disease/population; rarity is an important 
criterion that greatly impacts overall and annual patient cost, especially for study 
lasting more than 1 year. Below 1 year, the cost per patient remains quite similar 
between types of diseases/populations; 4) Cost are more significant in rare diseases 
studies, therefore DPC can provide the best overall cost savings in these populations; 
and 50 The cost savings are depended on the expected rate of patient LFU-with/
without DPC service and the planned patient sample size. ConClusions: Return 
On Investment plays an important role for Sponsors to determine if DPC is valu-
able in a study. The financial investment may be beneficial regardless of the cost to 
insure completion of the patients, thus meeting the scientific study objectives. But 
it could generate cost savings as well.
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objeCtives: Retrospective chart review studies can result in robust naturalistic 
data to inform evaluations of treatment patterns, resource utilization, costs of care, 
clinical outcomes and safety. Data quality control is challenging both as a result of 
poor quality documentation in the usual care medical chart, or as a result of data 
abstraction and data entry processes. Methods: Ten chart review case studies con-
ducted in the United States, Canada and Europe were evaluated to provide recom-
mendations for improving chart review data quality control mechanisms. Results: 
All 10 studies used electronic data capture (EDC) systems. Common lessons learned 
across the studies were that the case report forms (CRFs) should only include neces-
sary data points required to fulfill the analysis. Direct chart-to-EDC data entry and 
remote real-time data quality control is recommended to reduce additional tran-
scription errors that may occur if using paper CRFs. It is important to ensure the EDC 
system includes a cohort-control platform that enables selection of patient cohorts 
(i.e., random selection) and tracking of eligibility screening to reduce selection bias 
